The first useful thing to know about Patrick Roberts is that his career has moved in a circle, though not the sort that returns to where it began. It is closer to the cell cycle he has spent years studying: a sequence of checkpoints, handoffs and decisions, repeated with enough variation to create something new. In 2009, Roberts and a small group of scientists worked shoulder-to-shoulder in incubator space at the University of North Carolina at Chapel Hill. Their company, then called G-Zero Therapeutics, would become G1 Therapeutics. A sentence on the lab whiteboard supplied the morale: “Today is a good day to cure cancer.”
Roberts was already an unusual fit for the usual scientist box. He had earned a PharmD from the University of Kentucky in 2002, then crossed from the practice of pharmacy into research, completing a PhD in pharmaceutical sciences at UNC in 2007. His doctoral work examined molecular signals associated with relapse and metastasis in lung cancer. The combination gave him two habits of mind: the pharmacist’s attention to how a medicine behaves in a person, and the researcher’s impatience with an answer that has not survived an experiment.
At G1, those habits met the unruly business of building a drug company. Roberts moved through roles as senior scientist, associate director, director and senior director of translational medicine. The titles changed; the connecting task did not. Translational medicine sits at the hinge between a plausible mechanism and a useful treatment. It asks which patients might respond, what evidence would show it, and whether the signal seen in a model can endure the trip into a clinical trial.
“CDK2 is a known driver of cancer cell proliferation and a target with broad clinical potential.”Patrick Roberts, on the INX-315 investigational program
A first trip around the cycle
The early G1 team focused on cyclin-dependent kinases, or CDKs, enzymes that act like timed switches as cells grow and divide. Their work produced three compounds that entered clinical development. Roberts made early scientific contributions to the idea of temporarily arresting blood-forming stem and progenitor cells during chemotherapy, and later served as project leader for trilaciclib. In plainer terms, the team explored whether carefully stopping healthy cells at the right moment could help protect them while chemotherapy did its work elsewhere.
Roberts followed trilaciclib from discovery toward patients. FDA meeting records later placed him in the room as G1’s senior director of translational medicine during discussions about a New Drug Application. The medicine, sold as Cosela, received FDA approval in February 2021. By then Roberts had left G1, but the arc mattered: he had seen a molecule travel through the successive gates of biology, development, regulation and clinical use. Few careers offer a more expensive education in the difference between an interesting result and an approvable medicine.
The lesson Roberts carried forward was not that drug development becomes predictable once one has done it. It was that an experienced team can ask sharper questions sooner. In 2020 he reunited with Jay Strum, John Bisi and Fred Eshelman to form what was first known as ARC Therapeutics and soon became Incyclix Bio. Their old whiteboard line received a confident edit: “Today is an even better day to cure cancer.” A little sentimental, perhaps, but sentiment is allowed when it has survived an NDA.
The escape route
Incyclix chose a target adjacent to the team’s earlier work but technically stubborn: CDK2. Several approved treatments inhibit CDK4 and CDK6, proteins that help regulate a key transition in the cell cycle. Yet some tumors depend on CDK2 or turn to it as a workaround. Resistance, in this view, is not a dramatic jailbreak. It is a cell finding another door in a familiar corridor.
The chemistry is unforgiving because CDK family members resemble one another, particularly around the pockets where inhibitors bind. A compound intended for CDK2 can hit relatives it was meant to spare. Incyclix’s lead candidate, INX-315, was designed as an oral, potent and selective small molecule. Published work describes how the team iterated from the structure of trilaciclib, changing the molecule across many design cycles until it arrived at a clinical candidate with the desired CDK2 activity and selectivity.
CDK4/6 and CDK2 help govern progression around this circuit. Incyclix is studying whether selective CDK2 inhibition can interrupt specific tumor dependencies and resistance routes.
A selective tool is only part of the problem. The company also needs to know where to use it. One group of interest carries amplification of CCNE1, the gene that encodes cyclin E1, a partner of CDK2. Another includes breast tumors that have progressed after a CDK4/6 inhibitor. This is where Roberts’s translational training becomes corporate strategy. The biomarker is not decoration added after the molecule; it helps define the trial, the collaborators and the evidence the company is trying to produce.
“By leveraging cell cycle biomarkers, we hope to be able to identify patients that will benefit most from combination treatments.”Patrick Roberts, 2025
A company built as a network
Incyclix is a compact organization attempting a large coordination problem. Its Phase 1/2 study of INX-315 spans clinical centers in the United States and Australia. Academic collaborators have examined the drug in preclinical models. A trial agreement with Eli Lilly added a combination arm using INX-315 with abemaciclib and fulvestrant. Investors have included Eshelman Ventures, RA Capital Management, Boxer Capital, Eli Lilly, Pharmacosmos, Cape Fear BioCapital and Hatteras Venture Partners.
Roberts’s public description of how the company works with key opinion leaders is revealing. He emphasizes collaboration, referrals and outreach, then matches each expert to the problem they know best. The relationships continue through dialogue, data sharing and new research questions. It is less a celebrity advisory board than an operating network. In biotechnology, the molecule may be proprietary; the intelligence required to develop it is inevitably communal.
That network has delivered a sequence of concrete gates. The FDA cleared Incyclix’s investigational application in early 2023. A first-in-human Phase 1/2 trial followed. Peer-reviewed research in Cancer Discovery in 2024 described INX-315’s design and activity in models. Interim monotherapy data were presented at the San Antonio Breast Cancer Symposium later that year. A 2025 Nature Communications paper examined biomarkers and the varied ways cancer-cell contexts respond to CDK2 inhibition.
FDA clears the INX-315 investigational application; Phase 1/2 work begins.
Peer-reviewed preclinical work and interim monotherapy data enter public view.
Fast Track designation, biomarker research, a Lilly combination and new financing advance the program.
An additional $5 million Series B investment supports completion of the ongoing study.
In April 2025, the FDA granted INX-315 Fast Track designation for a biomarker-defined ovarian-cancer setting. In August, Incyclix raised an $11.25 million extension to its Series B. The following April, Hatteras Venture Partners added $5 million. Fast Track is not approval, interim data are not final data, and financing is not scientific validation. Each is nevertheless a useful permission slip for the next piece of work. Roberts’s job is to keep those permissions arriving in the correct order.
The operator at the hinge
Roberts does not present himself as a lone inventor. His record is full of co-authors, co-founders, investigators and institutional handoffs. Even the company’s founding tale uses “we.” This is appropriate. A clinical-stage medicine is an argument assembled by many hands, with chemistry, animal models, patient data, manufacturing and regulatory logic all required to agree closely enough.
What distinguishes Roberts is the span of the argument he has learned to read. Pharmacy placed the patient at one end. Doctoral research placed molecular evidence at the other. G1 filled in the long, messy middle. At Incyclix he now occupies the chief executive’s version of translational medicine: deciding how scientific claims become programs, how programs earn capital, and how capital becomes another chance to collect evidence.
The latest version of the Incyclix story is still being written inside a clinical trial. Its lead molecule has crossed important thresholds, but the decisive questions remain empirical. That uncertainty is not a flaw in the plot. It is the plot. Roberts and his colleagues have returned to the cell cycle with better maps, an old working rhythm and a target that resisted simpler approaches.
A whiteboard is a cheap piece of laboratory equipment. It is also where a team makes uncertainty briefly legible. Seventeen years after the original G1 crew began sharing incubator space, Roberts is still working from the same basic proposition: identify the next checkpoint, gather the right people, and make the next claim earn its place. The sentence on the board got one extra word. The work beneath it became considerably more exact.